General Information
Arrowhead 3003 SHASTA-3
AROAPOC3-3003 Double-Blind, Placebo-Controlled, Phase Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Severe Hypertriglyceridemia (SHASTA-3 Study)
| Protocol | AROAPOC3-3003 |
|---|---|
| Identifier | |
| UID | efbae3df-3c13-4616-94dc-3f888e2dbff3 |
| Status | Follow-up |
| Phase | 3 |
| Category | Hypertriglyceridemia / Adult |
| Launch Year | 2024 |
| NCT Number | - |
| Created | 2024-03-12 15:27 |
| Last Updated | 2025-05-06 14:50 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2025-05-06 | No |
| Enrollment Open | 2024-07-15 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2024-07-09 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | No | |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Gomez, Kathie | KGomez | No |
| Coordinator | Bell, Aramis | ABell | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Arrowhead Pharmaceuticals |
|---|---|
| Division | Arrowhead Pharmaceuticals |
| Team | Arrowhead Pharmaceuticals |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | IQVIA RDS Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | PaleGoldenrod |
| Currency | - |
